Giulia Monticone

TL;DR: This review will present the newest mechanistic and therapeutic advances in the Notch field and discuss the promises and challenges of this constantly evolving field.

TL;DR: A new immunosuppressive pathway in which adenosine promotes Casitas B-lineage lymphoma b (Cbl-b)-mediated Notch1 degradation, causing suppression of CD8+ T-cells effector functions is described, providing evidence that targeting the Cbl- b-Notch1 axis is a novel promising strategy for cancer immunotherapy.

TL;DR: This work demonstrates that targeting Cbl-b-Notch1 axis is a novel promising strategy for cancer immunotherapy, in which activation of Notch1 results in enhanced CD8+ T-cell effector functions, anti-cancer response and resistance to immunosuppression.

TL;DR: This study shows that Mc significantly reduced Arg1 and iNOS in bone marrow (BM)-derived MDSCs both at the mRNA and protein levels, and proposes repurposing Mc at metronomic doses as a new approach to enhance efficacy of immunotherapy for patients with MSI colon cancer.

TL;DR: It is suggested that promoting Notch1 signaling by blocking Cbl-b-mediated degradation results in increased T-cell responses and resistance to immunosuppression, and Targeting Cblb-Notch1 axis represents a promising novel strategy to boost anti-cancer T- cell responses.